Articles related to OBESITY/WEIGHT MANAGEMENT

The significant reduction in the incidence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke highlights the need for further research into the benefits of semaglutide in this patient population.

This study suggests that a positive approach, presenting weight loss treatment as an opportunity, may be more effective in encouraging patients to take up treatment and achieve weight loss.

The Yale Food Addiction Scale (YFAS) identified a prevalence of food addiction reaching 32% in people with obesity having bariatric surgery.

Stay informed about the potential risks associated with popular weight loss drugs. Ensure patient safety by monitoring for symptoms of depression and suicidal ideation.

New reports and studies are raising concerns about the gastrointestinal safety of semaglutide-containing medications; clinicians are advised to exercise caution and monitor patients for symptoms of gastroparesis.

This study offers valuable insights into the comparative efficacy and safety of apixaban and rivaroxaban in obese patients with NVAF, highlighting the need for a patient-centered approach in anticoagulant selection.